Stroke is a major cause of death and disability in the US. Unfortunately, current therapeutic options are seriously limited. Emerging evidence shows that post-ischemia angiogenesis plays a crucial role in the recovery of blood flow and neuronal metabolism after stroke. Thus, promoting angiogenesis via various approaches appears as a promising treatment for experimental ischemic stroke. MicroRNAs (miRs) function as a novel class of noncoding small RNAs that negatively modulate protein expression. MiRs have been implicated in a variety of human neurological diseases. Recent studies have revealed important roles for miRs in regulating angiogenesis. We and others have shown the involvement of miRs in the pathogenesis of ischemic brain injury, suggesting miRs as potential therapeutic targets in stroke. However, the functional significance and mechanisms of miR molecules in the regulation of angiogenic processes after stroke are poorly understood. The miR-15a/16-1 cluster is the first identified miR group associated with human carcinogenesis. Recently, dysregulated plasma miR-15a/16-1 levels are found in stroke patients, showing great potential as diagnostic and prognostic biomarkers. Inhibition of miR-15 has been shown to protect against myocardial infarction (MI). Thus, several pharmaceutical companies (MiRagen therapeutics; Servier) consider miR-15 as an important miR target to develop miR-based drugs for improving post-MI recovery. We reported for the first time that endothelial miR-15a can significantly suppress cell-autonomous angiogenesis in hindlimb ischemia. Moreover, our preliminary studies showed that the levels of the miR-15a/16-1 cluster are significantly increased in the cerebral vasculature at the penumbral area 7d after middle cerebral artery occlusion (MCAO) in mice. Of note, EC-selective miR-15a/16-1 transgenic overexpression leads to reduced cerebral microvessels and increased brain infarction in mice 7d after MCAO. Furthermore, we found that the miR-15a/16-1 cluster can bind to the 3'-UTR of vascular endothelial growth factor (VEGF) mRNA and inhibit its protein expression. These findings prompt the central hypothesis that the miR-15a/16-1 cluster functions as a critical regulator in post-ischemic cerebral angiogenesis, thus affecting long-term neurological outcomes after ischemic stroke.
Three aims will be performed in this proposal.
Aim 1 : Determine the functional role of the miR-15a/16-1 cluster in regulating post-stroke angiogenesis;
Aim 2 : Identify the molecular targets of the miR- 15a/16-1 cluster in regulating post-stroke angiogenesis;
Aim 3 : Determine whether miR-15a/16-1-mediated angiogenesis affects long-term stroke outcomes.

Public Health Relevance

Stroke is the fourth most common cause of death and the leading cause of adult disability in the United States. Currently, acute therapeutic interventions are limited to thrombolytic therapy within a narrow time window and development of effective therapies is urgently required. The object of this application is to test our hypothesis that the miR-15a/16-1 cluster functions as a critical regulator in cerebral angiogenesis and affects long-term neurological outcomes after ischemic stroke. The successful implementation of this proposal will elucidate the functional importance of miR-15a/16-1-mediated post-stroke angiogenesis and may eventually lead us to discover novel pharmaceutical targets to mediate angiogenesis with promise for further development of neurorestorative therapies after ischemic stroke.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project (R01)
Project #
5R01NS091175-03
Application #
9063624
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
Koenig, James I
Project Start
2015-11-11
Project End
2020-03-31
Budget Start
2016-04-01
Budget End
2017-03-31
Support Year
3
Fiscal Year
2016
Total Cost
Indirect Cost
Name
University of Pittsburgh
Department
Neurology
Type
Schools of Medicine
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Sun, Ping; Liu, Da Zhi; Jickling, Glen C et al. (2018) MicroRNA-based therapeutics in central nervous system injuries. J Cereb Blood Flow Metab 38:1125-1148
Cai, Wei; Yang, Tuo; Liu, Huan et al. (2018) Peroxisome proliferator-activated receptor ? (PPAR?): A master gatekeeper in CNS injury and repair. Prog Neurobiol 163-164:27-58
Zhang, Xuejing; Hamblin, Milton H; Yin, Ke-Jie (2018) Noncoding RNAs and Stroke. Neuroscientist :1073858418769556
Zhang, Wenting; Chen, Ruiying; Yang, Tuo et al. (2018) Fatty acid transporting proteins: Roles in brain development, aging, and stroke. Prostaglandins Leukot Essent Fatty Acids 136:35-45
Tan, Zhou; Li, Jingya; Zhang, Xuejing et al. (2018) P53 Promotes Retinoid Acid-induced Smooth Muscle Cell Differentiation by Targeting Myocardin. Stem Cells Dev 27:534-544
Tang, Xuelian; Liu, Kai; Hamblin, Milton H et al. (2018) Genetic Deletion of Kr├╝ppel-Like Factor 11 Aggravates Ischemic Brain Injury. Mol Neurobiol 55:2911-2921
Hu, Xiaoming; De Silva, T Michael; Chen, Jun et al. (2017) Cerebral Vascular Disease and Neurovascular Injury in Ischemic Stroke. Circ Res 120:449-471
Zhang, Xuejing; Tang, Xuelian; Liu, Kai et al. (2017) Long Noncoding RNA Malat1 Regulates Cerebrovascular Pathologies in Ischemic Stroke. J Neurosci 37:1797-1806
Zhang, Xuejing; Hamblin, Milton H; Yin, Ke-Jie (2017) The long noncoding RNA Malat1: Its physiological and pathophysiological functions. RNA Biol 14:1705-1714
Yang, Xinxin; Tang, Xuelian; Sun, Ping et al. (2017) MicroRNA-15a/16-1 Antagomir Ameliorates Ischemic Brain Injury in Experimental Stroke. Stroke 48:1941-1947

Showing the most recent 10 out of 14 publications